Immunological and virological changes in antiretroviral naive human immunodeficiency virus infected patients randomized to G-CSF or placebo simultaneously with initiation of HAART

Scandinavian Journal of Immunology

Volumn 51, Issue 5, 2000, Pages 520-525

  Aladdin, Hassan ^a,b   Ullum, H ^a   Katzenstein, T ^a   Gerstoft, J ^a   SkinhOj P ^a   Klarlund Pedersen, B ^a  

^a Mental Health Services CPH   (Denmark)

^b M7641   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEMORY CELL; NATURAL KILLER CELL; NEUTROPHIL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION; VIRUS DETECTION;

ADULT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; GRANULOCYTE COLONY-STIMULATING FACTOR; HIV INFECTIONS; HIV-1; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTES; MIDDLE AGED; NEUTROPHILS; RNA, VIRAL;

EID: 0034013479     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2000.00718.x     Document Type: Article

References (12)

1. + T-cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
2. 2 Palella FJJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Invest N Engl J Med 1998;338:853-60.
3. 3 Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-9.
4. 4 Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA 1998;280:72-7.
5. 5 Nielsen SD, Afzelius P, Dam-Larsen S et al. Effect of granulocyte colony-stimulating factor (G-CSF) in human immunodeficiency virus-infected patients: increase in numbers of naive CD4 cells and CD34 cells makes G-CSF a candidate for use in gene therapy or to support antiretroviral therapy. J Infect Dis 1998;177:1733-6.
6. 6 Hartung T, Pitrak DL, Foote M, Shatzen EM, Verral SC, Wendel A. Filgrastim restores interleukin-2 production in blood from patients with advanced human immunodeficiency virus infection. J Infect Dis 1998;178:686-92.
7. 7 Hermans P, Rozenbaum W, Jou A et al. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. G-CSF 92105 Study Group AIDS 1996;10:1627-33.
8. 8 Kuritzkes DR, Parenti D, Ward DJ et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group AIDS 1998;12:65-74.
9. 9 Aladdin H, Ullum H, Neilsen S et al. G-CSF increases CD4+ T-cell counts in HIV-infected patients on stable highly active antiretroviral therapy (HAART): results from a randomized, placebo-controlled study. J Inf Dis, in press.
10. 10 Stricker RB, Goldberg B. Increase in lymphocyte subsets following treatment of HIV-associated neutropenia with granulocyte colony-stimulating factor. Clin Immunol Immunopathol 1996;79:194-6.
11. 11 Gabrilove JL, Jakubowski A, Fain K et al. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 1988;82:1454-61.
12. 12 Kerrigan DP, Castillo A, Foucar K, Townsend K, Neidhart J. Peripheral blood morphologic changes after high-dose antineoplastic chemotherapy and recombinant human granulocyte colony-stimulating factor administration. Am J Clin Pathol 1989;92: 280-5.